New review article on the management of relaps... - CLL Support
New review article on the management of relapsed/refractory chronic lymphoctyic leukemia
You need to be a member of this community to see this post.
Read more about...
8 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
BRUIN Study: phase 1/2 study of Pirtobrutinib (formerly Loxo 305) in relapsed or refractory B-cell malignancies
previous covalent BTK inhibitor resistance 67%, covalent BTK inhibitor intolerance 52%, BTK...
Time-Limited Triplet Emerges as a Potential Standard in Relapsed/Refractory CLL
standard of care for patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who have...
Relapse/Refractory CLL
frontline (initial) treatments, there are somewhat limited options for Relapse/Refractory CLL (just...
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE)
(p=0·020). Remember these are relapsed and refractory patients.
Two patients in the ublituximab...
Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm
chemoimmunotherapy for CLL. This paper gives an overview of novel targeted agents used for CLL...
Related Posts
Alterations of the immune system caused by CLL B‐cells 
New Review Article about Venetoclax
Phase I/II trial of IPH2201 checkpoint inhibitor in combination with ibrutinib opens for patients with relapsed or refractory CLL
A New Era is Coming up in the Treatment of Chronic Lymphocytic Leukemia
Ibrutinib Slow but steady foreward movement.
